Agenda/Recordings

Daily Recordings

click each green title to see that presentation on YouTube

Wed., Feb. 23, 2022 Thu., Feb. 24, 2022 Fri., Feb. 25, 2022

Wed., Feb. 23, 2022

EVENT	PRESENTER(S)
Welcome to Conference & CCF Update	Jesper B. Andersen, University of Copenhagen and Lipika Goyal, Massachusetts General Hospital, Stacie Lindsey, Cholangiocarcinoma Foundation
Cholangiocarcinoma Foundation Volunteer Recognition Ceremony	Cindy Thomas, and Claire Condrey, Cholangiocarcinoma Foundation
Caregiver Perspective	Jim McMahon
Clinical Update	Lipika Goyal, Massachusetts General Hospital
Scientific Update	Jesper B. Andersen, University of Copenhagen
Panel Discussion	Jesper B. Andersen, Lipika Goyal, and Stacie Lindsey
Patient Perspective	Scott Stennett
CholangioConnect Update	Patty Maxin, Cholangiocarcinoma Foundation
Advocacy Update	Melinda Bachini, Cholangiocarcinoma Foundation
Patient Registry: Importance of Contributing Your Data for Research	Conner O'Brien, Lynette McMahon and Melinda Bachini

Thu., Feb. 24, 2022

EVENT	PRESENTER(S)
Conference Welcome, CCF Update and Awards Ceremony	Jesper B. Andersen and Stacie Lindsey
Patient Perspective	Marisa Wilson
Session I :: Listening to Your Gut: The Influence of the Microbiome	Moderator: Lewis Roberts, Mayo Clinic
The Microbiome and Cholangiocarcinoma	Tim Greten, NIH
Why Should Oncologists Care about the Microbiome	Gregory Sepich-Poore, University of California, San Diego - School of Medicine
The Role of the Microbiome in Predicting Immunotherapy Response	Katie Kelley, UCSF
Panel Discussion
TOPAZ-1 Trial in Biliary Tract Cancer	Do-Youn Oh, Seoul National University Hospital
Session II :: Studying the Neighborhood: Lessons from the Tumor Microenvironment	Moderator: Mario Strazzabosco, Yale School of Medicine
What is the Tumor Microenvironment and Why does it Matter in Cholangiocarcinoma?	Nilo Azad, Johns Hopkins Medicine
Successes, Failures, and Future Ideas for Targeting the Tumor Microenvironment in Cancer	Sumera Ilyas, Mayo Clinic
Insights into Immunoregulation in the Liver	Niklas Bjorkstrom, Karolinska Institutet, Sweden
Panel Discussion
Caregiver Perspective	Ambuj Srivastava
Session III :: Targeted Therapies and Overcoming Resistance	Moderators: Ghassan Abou Alfa, MSKCC and Lipika Goyal, Massachusetts General Hospital
The Hottest Targeted Therapies on the Horizon for Cholangiocarcinoma	Rachna Shroff, University of Arizona
Novel Approaches to Overcoming FGFR Resistance in FGFR-altered Cholangiocarcinoma	Francesco Facchinetti, Gustave Roussy Cancer Center, France
Why we Need Correct ICD Coding for Cholangiocarcinoma	Shahid Khan, Imperial College London, UK
Cancer Genome Sequencing U2C Cancer Moonshot Program	Ryan Fields, Washington University at St. Louis
Panel Discussion
Cholangiocarcinoma Foundation Research Fellowship Reports: Session #1
History of Cholangiocarcinoma Foundation Research Fellowship Program	Nabeel Bardeesy, Massachusetts General Hospital
Deciphering the Role of Cancer-Associated Myeloid Cells in Resistance to Immunotherapy in Biliary Cancer	Bridget Keenan, University of California, San Francisco
Clonal Origins of Metastatic Cholangiocarcinoma	Christopher Chen, Stanford University
Session IV :: Epigenetics: Now or Never?	Moderator: Jesper B. Andersen, University of Copenhagen and Katie Kelley, UCSF
GL Alterations in BTC; Previously Underappreciated and Possibly Targeted	Ghassan Abou-Alfa, MSKCC
Targeting IDH1 Version 2.0	Maeve Lowery, University of Dublin, Ireland
Is the Epigenome a Driver of Cholangiocarcinoma?	Stephanie Roessler, University of Heidelberg, Germany
Novel Epigenetic Targets in the Clinical Setting Besides IDH1	Li-Tzong Chen, National Institute of Cancer Research, Taiwan
Panel Discussion

Fri., Feb. 25, 2022

AGENDA	PRESENTER(S)
CCF Communications Update	Jennifer Weaver, CCF
Session V :: Thinking Big: Transformative Approaches to Curing Cholangiocarcinoma	Moderators: Rocio Macias, University of Salamanca, Spain and Chiara Braconi, Glasgow University, UK
Transformative Approaches to Clinical Trial Design	Juan Valle, University of Manchester, UK
The Role of ctDNA in Promoting a Cure for Cholangiocarcinoma	Zachariah Foda, Johns Hopkins Medicine
Bridging the Gap: Using Models to Push for a Cholangiocarcinoma Cure	Luke Boulter, University of Edinburgh, UK
Panel Discussion
Session VI :: Multi-Disciplinary Case-Based Discussion	Moderators: Milind Javle, MD Anderson Cancer Center and Flavio Rocha, Oregon Health and Science University
Multi-Disciplinary Case-Based Discussion	Tin-Yun Tang, MD Anderson Cancer Center John Bridgewater, University College London Ethan Ludmir, MD Anderson Cancer Center Riad Salem, Northwestern University Talia Baker, University of Utah Huntsman Cancer Institute
ICRN Program Update	Mitesh Borad, Mayo Clinic and Nilo Azad, Johns Hopkins Medicine
Caregiver Perspective	Laura Lee
Komodo Update	Melissa Agnello, Komodo Health
Global CCA Database	Shishir Maithel, Emory University
CCF Research Fellowship Reports: Session #2	Moderator: Katie Kelley, UCSF
Deep Immune Profiling of Intrahepatic Cholangiocarcinoma with CODEX Multiplexed Imaging	Mark Yarchoan, Johns Hopkins Medicine
Explore Signaling Pathways and Combination Therapy in FGFR2-activated Cholangiocarcinoma	Qibiao Wu, Harvard University
Investigating the Role of YAP1 Signaling in Shaping the Tumor Immune Landscape of Intrahepatic Cholangiocarcinoma	Miguel Ángel Martin, Icahn School of Medicine at Mount Sinai
Panel Discussion
2022 Fellowships Announcements	Katie Kelley, University of California, San Francisco
Conference Closing	Jesper B. Andersen, Lipika Goyal and Stacie Lindsey